Innoviva (INVA)
(Delayed Data from NSDQ)
$18.19 USD
+0.52 (2.94%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $18.18 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INVA 18.19 +0.52(2.94%)
Will INVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INVA
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Is Innoviva (INVA) Stock Undervalued Right Now?
INVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
Other News for INVA
Top 5 Value Stocks For A Big Tech Pullback (SA Quant)
FHLC: Healthcare Dashboard For July
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Innoviva: Potentially Overvalued
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs